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The purpose of this research was to (a) examine the demographics of patients receiving 
care in an outpatient cardiology clinic, (b) describe the relationship between the atrial fibrillation 
(AF) and other variables (e.g., BMI), (c) examine the frequency and the length of time to AF 
diagnosis in patients implanted with an implantable cardiac monitoring (ICM) device, (d) 
observe provider patterns of treatment with oral anticoagulants (OACs), and (e) investigate 
documented considerations to either diagnose or rule out OSA in a group of outpatient AF 
patients in a cardiology clinic. 
Background:  AF is largely undiagnosed but can cause major morbidity and mortality.  AF is 
the most prevalent sustained arrhythmia encountered in the emergency department, is frequently 
detected in those without a prior diagnosis of AF, and is the most common cause for stroke.  All 
relevant guidelines suggest patients from intermediate to high risk for stroke should receive 
OAC; however, this therapy is prescribed in less than 55% of eligible patients.  AF accounts for 
nearly 1 in 7 strokes and affects approximately 5.8 million people in the United States. 
Objectives:  The purpose of this study is to identify and intervene in patients with atrial 
fibrillation using an implantable cardiac monitor to significantly improve guideline-based 
anticoagulation therapy. 
Methods:  A retrospective database from an outpatient clinic in southern California was 
analyzed in this non-experimental study design; it comprised routinely-collected data on patients 
with ICMs implanted between June 1, 2014 and December 31, 2018.  This study was designed to 
establish the incidence of AF using an ICM device (i.e., Medtronic LINQ) in the outpatient 
setting.   
  
Conclusions:  As evidenced by this study, most patients would not have been diagnosed with AF 
utilizing the shorter-duration monitoring devices typically used as the first line of treatment.  
Longer monitoring capabilities promise early identification of disease and reduction in morbidity 
for AF patients. 
Discussion:  The incidence of AF using an ICM (i.e., Medtronic LINQ) device in an outpatient 
clinic was 23.4% (63 out of 269 patients), similar to national studies stating that longer 
monitoring of cardiac rhythms increased the diagnosis of arrythmias.  Only 12.7% of detected 
AFs (11 out of 63 patients) occurred before 14 days, the maximum time available through the 
use of other, traditional monitoring devices in standard use; therefore, an alarming 87.3% of 
ICM-detected arrythmias could have remained unidentified.  This research observed a reduction 
of potential, highly-debilitating embolic stroke through detection as well as a lessened risk of all-
cause mortality with OACs for AF patients without stroke prophylaxis; early identification and 
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Statement of the Problem 
The purpose of this study is to identify and to provide early intervention with patients at 
high risk for nonvalvular atrial fibrillation (AF) with implantable cardiac monitoring devices 
(ICM) and significantly improve treatment with guideline-based oral anticoagulation (OAC).  AF 
affects 1% to 2% of the general population and the prevalence is increasing worldwide, due in 
part to the aging population (Colilla, Crow, Petkun, Singer, Simon, & Liu, 2013).  This number 
is estimated to double by 2050 (Miyasaka, Barnes, & Gersh, 2006). The cost of care for patients 
with AF are substantial. Estimates range from $6 billion to $26 billion a year of which $6 billion 
was attributed directly to AF and $9.9 billion to other cardiovascular expenses (Mozaffarian, 
Benjamin, & Go, 2015).  AF is often asymptomatic, paroxysmal, or both (Barbarossa, Guerra, & 
Capucci, 2014); therefore, the arrythmia goes undetected until major complications arise and/or 
patients become disabled.  In some cases, the diagnosis of thromboembolism/ stroke may be the 
first identification of AF.  AF is associated with a four- to five-fold increase in risk for 
thromboembolism (Wolf, Abbott, & Kannel, 1991). Thromboembolism/stroke is a leading cause 
of long-term disability and can lead to irreversible harm such as memory loss, altered 
psychological status, speech/language difficulty, and disability/paralysis (Mozaffarian et al., 
2015).  Early identification and treatment of patients with AF are essential in decreasing 
devasting effects from thromboembolic disease.  With the Internet, smart phones, and other new 
ways of detection, AF can be identified more frequently, but currently there are no protocols or 
guidelines to diagnosis this elusive arrythmia.  The inability to provide timely identification or 
diagnosis of AF is imperative and supports the purpose of this research study.  The goal of this 
research project is to determine the most specific and accurate method(s) for the early 
  
identification of AF; newer forms of detection have inaccurately provided noise where they are 
typically a warning and a way for further investigation by a licensed practitioner.  When AF is 
symptomatic, detection is straightforward because the symptoms often include palpitations, 
syncope, chest pain, or shortness of breath.  These symptomatic cases are typically diagnosed 
and treated quickly due to the patient’s ailing complaints and presentation to the health care 
practitioner.  Nonetheless, AF is most often asymptomatic and therefore is largely undiagnosed 
until the occurrence of major morbidity or mortality through thromboembolism or heart failure 
(HF).  Improved guideline-based therapy could directly reduce the risk of a potential, highly 
debilitating thromboembolism in AF patients.   
This study will commence with a description of the scope and significance of AF.  A 
discussion ensues for more timely identification of AF with ICM and approaches for continued 
follow up for patients with AF. These sections will be followed by a review of the literature that 
support the rationale for this study.   
Background and Significance 
The purpose of this research is to add knowledge to the early detection of AF and to 
assist in decreasing morbidity and mortality and advancing timelier treatment of AF with oral 
anticoagulants, procedures, and treatments using ICMs to identify arrythmias.  Currently, no 
protocols or guidelines exist on the diagnosis of AF or the type of monitoring device to use.  
Presently, the provider selects the monitoring device based on comfort and knowledge of the 
products.  Monitors vary in duration of surveillance for cardiac rhythms, from seconds up to 3 
years.  As the population ages, the prevalence of AF increases as does the sequela of AF’s 
morbidity and mortality effects.  The U.S. population aged 65 years and over grew from 35.0 
million in the year 2000 to 49.2 million in the year 2016; expectations are for continued growth 
  
in this population sector (U.S. Census Bureau, 2017).  The median age in the United States is 
expected to grow from 38 years old today to 43 years old by 2060 (U.S. Census Bureau, 2018). 
AF is the most prevalent sustained arrythmia encountered in emergency departments 
(EDs) and outpatient clinics; 3.6% to 7.0% of general emergency visit (Coll-Vinent, Malagon et 
al., 2007).  Currently there is no implementation of common guidelines at various care levels to 
improve AF treatment (Coll-Vincent, Pacheco et al., 2007).  AF is defined by the American 
Heart Association as a heart arrythmia where the upper chambers of the heart (the atria) beat 
irregularly instead of beating effectively to move blood into the ventricles (American Heart 
Association, n.d.).  AF can decrease the heart’s pumping capacity by as much as 30% (Harvard 
Medical Publications, 2018).  When blood does not move effectively, it can become stagnant and 
thickened to form thrombus (i.e., clot) that could lead to dangerous thromboembolic events.  The 
blood cells adhere to each other and form clots in the left atrial appendage (LAA) of the heart 
(Blackshear, & Odell, 1996).  When the thrombus escapes from the LAA, it then can travel to 
other areas of the body, cut off blood supply, and cause a stroke (Cleveland Clinic, n.d.).  AF can 
be persistent, paroxysmal, or permanent.  Persistent AF lasts longer than 1 week.  The arrythmia 
may stop on its own or require medical therapy.  Paroxysmal/intermittent AF is spontaneously 
and terminates in less than 7 days.  Permanent AF continues and cannot be corrected.  AF may 
be symptomatic, but is often asymptomatic.  Up to one-third of all individuals with AF may not 
be aware of their condition (Steinhubl, Waalen, Edwards, Mehta et al., 2017).  Symptomatic AF 
is often described as palpations, syncope, chest discomfort, fatigue, and shortness of breath.  
Symptomatic AF is favorable because it can be detected and treated more efficiently.  
Asymptomatic AF is usually identified after having an embolic event, positive random ECG, or 
HF exacerbation; therefore, the disease is challenging to diagnosis and treat.  The correlation 
  
between symptoms and AF is unreliable for disease recognition.  Patients with AF typically have 
other cardiovascular comorbidities (e.g., HF, obstructive sleep apnea [OSA]).  These patients are 
at elevated risk of cardiovascular and thromboembolic events and mortality when compared with 
non-AF patients (Benjamin et al., 1998).  Patients with AF are 5 times more likely to have a 
stroke than those who do not have AF (National Stroke Association. n.d.).  The purpose of 
researching ICM and AF detection is to identify patients with AF earlier, increase treatment rates 
per guidelines, and increase knowledge by having constant electrocardiogram (ECG) capability.  
A study by Ziegler, Koehler, and Mehra (2006) demonstrated that extending the monitoring 
duration from 24 hours to 7 days significantly increased the AF detection rate. Additionally, 
according to Brignole et al. (2004), subcutaneous implantable monitors were largely accepted in 
clinical practice for diagnosing patients with unexplained syncope. Providers have a wealth of 
mechanisms when selecting a monitoring technique.  The options vary from 48-hour Holter 
monitors, 3- to 7-day telemetry monitors, watches, 7-day patches, and implantable devices.  The 
time needed to detect AF is still unknown; however, a recent CRYSTAL AF study reported 84-
126 days was needed on average (Sanna et al., 2014).  Providers are utilizing a haphazard 
approach in monitoring patients; therefore, are unable to identify an AF diagnosis.  The ICM 
could potentially help guide individual patient treatment (Lim, & Lip, 2008).   
Asymptomatic AF has major implications for society, can challenge national health care 
costs, and can require extra services post disease state.  The current mainstay in treatment for AF 
is anticoagulation, but other treatment modalities offer promising results, including intervention 
approaches (e.g., Watchman device, left atrium clip).  Diagnosis at older ages and/or with 
increased morbidity burden U.S. health care costs.  For AF-verses-control subjects, the mean 
annual inpatient cost-per-patient were $7,841 verses $2,622, outpatient medical costs were 
  
$9,225 versus $5,629, and outpatient pharmacy costs were $3,605 versus $3,714 (Benjamin et 
al., 1998).  The total incremental costs for AF were $8,705 per patient; the national incremental 
costs for AF were $26 billion (Benjamin et al., 1998).  
HF is a devastating outcome of AF; a chronic disease that must be managed with strict 
diet and daily medications.  HF develops in as many as 40% of patients with AF (Schnabel et al. 
2013; Wang et al., 2003).  Among patients aged between 55-74 years, the 10-year mortality was 
61.5% in men with AF compared to 30% in men without AF.  Among women in similar age 
group, the 10-year mortality was 57.6%, in the AF group verses 20.9% in women without AF 
(Stewart, Hart, Hale, & McMurray, 2002).  HF affects approximately 4.8 million people in the 
United States and Americans are spending over $17 billion annually on treatments for HF 
(American Heart Association, n.d.).  Patients are often readmitted to the hospital for HF 
exacerbation due to the difficulty in managing this disease.   
Treatment for AF typically includes rate control, rhythm control, and embolic stroke risk 
protection with OAC.  In patients with AF, 85%-90% may be candidates for OAC therapy 
(Freeman et al., 2015).  Treatment for AF begins with risk stratification of the embolic 
probability and calculated risk stratification score; an anticoagulant is prescribed depending on 
the guidelines.  Risk stratification involves assessing every patient for key elements, such as 
Congestive heart failure, Hypertension, Age, Diabetes, history of TIA or Stroke, Vascular 
disease, Age (again), and female Sex (CHA2DS2-VASc).  Each element contributes 1 or 2 points; 
a total score of 2 or greater indicates that the patient should be prescribed an OAC.  The higher 
the CHA2DS2-VASc risk score, the higher the embolic risk.  Often patients do well on OAC 
(e.g., Xarelto, Eliquis, coumadin); however, patients must understand the bleeding risks verses 
the embolic risk when taking OACs.  The bleeding risk often creates a dilemma with clinician 
  
prescribing habits; the need to evaluate the risk of bleeding versus possible legal action.  In the 
United States, multiple lawsuits have been filed alleging harm from blood thinners.  
Research Aims 
This research study examined data using the following study aims: 
AIM 1:  Describe the patient demographics (e.g., age, gender, ethnicity, AF) of patients receiving 
care in an outpatient cardiology clinic.   
AIM 2:  Describe the relationship between the dependent variable (AF) and independent 
variables (e.g., BMI) in patients receiving care in an outpatient cardiology clinic.   
AIM 3: Examine the frequency of AF diagnosis and the length of time to diagnosis in patients 
implanted with an ICM receiving care in an outpatient cardiology clinic.   
AIM 4:  Examine provider patterns of treatment with OACs. 
AIM 5:  Investigate documented considerations to diagnose or rule out OSA in a group of 
outpatient AF patients in a cardiology clinic. 
   
  
Chapter 2 
Review of the Literature 
The purpose of this chapter is to summarize the current literature about AF with 
comprehensive literature search using Cumulative Index to Nursing Allied Health Literature 
(CINAHL), Google Scholar, Ovid SP, PubMed, Cochrane database and evidence-based medical 
reviews and current literature in nationally recognized journals.  Key search terms were AF, 
cardiac monitors, cardioembolic events, and related terms. Additional articles from the reference 
sections were used from cited articles.  AF is largely undiagnosed and can cause major morbidity 
and mortality.  AF is the most common cause for stroke (Aguilar & Hart, 2008).  Of those 
patients with AF, their average yearly risk for stroke is 5%, and the risk is increased in the 
presence of certain risk factors, including left ventricular dysfunction, hypertension, increasing 
age, and history of stroke (Atrial fibrillation Investigators 1994) and now has increased with the 
addition of risk factors such as diabetes, gender, CAD, renal impairment, sleep apnea or chronic 
obstructive pulmonary disease and vascular history.  These are independent risk factors 
associated with increased stroke risk. (Mozaffarian, Benjamin, GO et al…)  AF is the most 
prevalent sustained arrhythmia encountered in the emergency department (ED) and outpatient 
clinic and is frequently detected in those without a prior diagnosis of AF (Coll-Vinent, Martin, 
Malagon, & HERMES-F Investigators, 2015).   
As the population ages, the risk for stroke increases (Mozaffarian et al., 2016).  The 
population is living longer therefore the age that providers see to treat becomes older and 
treatment is longer.  That is nearly 3 to 6 million people in the United States (Go et al., 2001).   
All relevant guidelines suggest patients that are intermediate to high risk for stroke 
should receive OAC (Stiell, & Macle, 2010).  Anticoagulation with warfarin was once the only 
  
choice but now there are novel oral anticoagulants that provide better cover and less interactions 
for patients.  When prescribing oral anticoagulants, the clinician balances the risk for bleeding 
and the risk for stroke in each patient individually.  Based on those risk the clinicians can pick 
from the variety of anticoagulants based on compliance, bleeding risk, availability and cost 
among other preferences.  Warfarin is often affected by the foods eaten or other medications 
prescribed or over the counter.  International ratio blood work is also needed regularly to monitor 
therapeutic levels while on warfarin.  With the new novel oral anticoagulants, patients are not 
restricted to a particular diet and do not have to monitor blood work while taking the OACS.  
Although anticoagulation is the goal in stroke prevention, often anticoagulation is not prescribed 
and if it is prescribed, the patients stopped taking the medication at 50% after 2 years 
(PINNACLE Registry Aug 2016).  Currently, anticoagulation is prescribed in less than 55% of 
eligible patients (Lane & Lip, 2012).  Forty percent of patients that were intermediate to high risk 
for stroke were under treated by receiving aspirin only (PINNACLE Registry Aug 2016).  AF 
accounts for nearly 1 in 7 strokes (Roldán et al. 2013) and affects about 5.8 million people in the 
United States (Colilla et al., 2012).  Therefore, the diagnosis is hard to identify and then, if the 
patient is diagnosed, appropriate treatment occurs less than 50% of the time.  Documentation is 
key to supporting an accurate diagnosis.  AF results in a five times greater risk of stroke and 
approximately 15% of strokes are due to AF (Wolf Abbott, & Kannel, 1991).  ICMs play a 
substantial role as a safety net for the management of AF.  Identifying AF is critical for guiding 
preventative therapy decisions.  We now have ICMs that can continuously monitor patients for 
several years and detect episodes of asymptomatic AF that are as brief as a few seconds. (Sanna, 
Diener, Passman et al 2014). These monitors could assist in early diagnosis and identification of 
with followed treatment.   
  
The Cryptogenic Stroke and Underlying Atrial Fibrillation study (CRYSTAL AF) 
assessed whether long term monitoring with an ICM was superior to standard monitoring for the 
detection of AF in patients with cryptogenic stroke at 6 months and 12 months.  This study also 
looked at providers actions post diagnosis of AF.  AF is defined as an irregular heart rhythm for 
more than 30 seconds without detectable p waves.  The researchers found 6.4 times more 
patients to have AF over 6 months using ICM.  They also noted the median time to AF detection 
was 84 days.  After the diagnosis of AF, the majority (97%) who had AF were prescribed OACs.  
In support of longer monitoring, the REVEAL AF was a prospective study of previously 
undiagnosed AF as documented by an ICM in high-risk patients (Reiffel et al. 2017).  AF is 
often silent and considered subclinical, therefore goes undetected until major morbidity and 
mortality occurs.  Recent studies showed AF and symptoms that only 13% to 21 % of episodes 
with symptoms suggestive of AF reported by patients with implanted pacemakers were AF 
episodes according to the pacemaker log. (Quirino at el., 2009). 
Use of intracardiac monitoring provides the clinician with daily ECGs for evaluation of 
arrythmias for longer periods of time.  Research on their use in the outpatient clinic setting is 
more limited.  In a recent abstract present at American College of cardiology, even the ECG 
patch found 9 times more AF than conventual means of monitoring.  They stated that the ECG 
patch had 5.1% rate of new AF diagnoses compared the usual controls at 0.6%. These 
researchers defined high risk patients as those 75 years or older, or at least 55 years old and male 
or 65 years old and female.  Those younger than 75 years old had to have a least one risk factor 
such as prior cerebral vascular event, heart failure, hypertension plus diabetes, or OSA. 
(Steinhubl, 2018).  
  
Risk factors such as congestive heart failure, hypertension, age, diabetes, history of TIA 
or stroke, vascular disease, and female gender have been identified and studied to increase 
embolic risk in patients with AF.  OSA is a popular topic in current literature as another possible, 
pertinent risk factor for patients with AF that increases embolic risk.  OSA is defined as a sleep 
disorder characterized by partial or complete obstruction of the airway due to the collapse of 
pharyngeal muscles, leading to the reduction of airflow (hypopnea) or complete absence of 
airflow (apnea; Mannarino, Di Filippo, and Pirro, 2012).  Sleep apnea is diagnosed when a 
patient experiences five or more episodes of hypopnea or apnea per hour during sleep along with 
associated symptoms, such as daytime sleepiness (Mannarino et al., 2012).  OSA has been linked 
to increase mortality and morbidity and associated with cardiac arrythmias, heart failure, and 
stroke (Butt, Dwivedi, Khair, and Lip, 2010).   
The STOP-BANG questionnaire is a valid and reliable tool to determine patients who are 
at risk for sleep apnea.  The questionnaire uses subjective and objective data points to calculate a 
risk score.  The screening tool assesses for snoring, tired, observed, body mass index >35kg/m2, 
age >50 years old, neck circumference >16 inches (41 cm), and male gender.  Scores are 
calculated as low risk (yes to 0-2 questions), intermediate risk (yes to 3-4 questions) and high 
risk (yes to 5-8 questions, or yes to 2 or more of 4 STOP questions and male gender, or yes to 2 
or more of 4 STOP questions and BMI > 35 kg/m2, or yes to 2 or more of 4 STOP 
questions and neck circumference ≥ 17 inches [43 cm] in males or 16 
inches [41 cm] in females).  A research AIM in this study examines 
patients who have OSA; these patients also have up to four times the 
risk of developing AF when compared to patients without OSA (Anter 
et al., 2017).  This study will test an innovative approach through the 
  
use of ICM to assure that newly-diagnosed AF patients in an 
outpatient clinic are diagnosed early and risk-stratified with a 
therapeutic plan for OAC, if applicable.  A cardiologist and 
cardiology nurse practitioner will use ICM data to improve the 
diagnosis of AF patients with prescribed stroke prophylaxis.  
Intracardiac monitoring is a novel and an innovative approach to 






The purpose of this research will add to the information on detecting AF earlier and assist 
in decreasing major morbidity and mortality by identifying AF earlier and treating with oral 
anticoagulants or procedures/treatments using ICMs to identify arrythmias.  This research will 
also investigate considerations for OSA in patients with AF.   
Study Design 
A retrospective database from an outpatient clinic in southern California was analyzed in 
this non-experimental study design; it comprised routinely-collected data on patients with an 
ICM implanted between June 3, 2014 and December 27, 2018.  This study was designed to 
establish the incidence of AF using an ICM device (i.e., Medtronic LINQ) in the outpatient 
setting.  To protect human subjects, Institutional Review Board approval was obtained from the 
University of San Diego.  Study limitations were also addressed.  All patients who received ICM 
devices from June 2014 through December 2018 in one outpatient cardiology clinic comprised 
this study population.  The non-experimental design was appropriate for this study to assess 
relationships among variables.  Patients initial demographics, diagnosis of AF, number of days 
from implant to AF event, implant justification, intervention with OACs, and assessment of sleep 
apnea risk were recorded and analyzed.  Once the diagnosis of AF was determined, a cardiology 
nurse practitioner calculated embolic and bleeding-risk assessment scores for each patient.   
In accordance with the 2014 ACC/AHA/ESC AF practice guidelines concerning patients 
with AF, the CHA2DS2-VASc score has been recommended to assess for stroke risk (January et 
al. 2014).  The CHA2DS2-VASc (i.e., Congestive heart failure history, Hypertension history, Age 
> 75, Diabetes mellitus history, previous Stroke or TIA symptoms, Age 65-74, Vascular disease 
  
history, and [female] Sex) is a risk-stratification tool that offers a comprehensive measurement 
(percentage) of a patient’s risk for an embolic event over the next year (Lip et al. 2010).  This 
tool is commonly used to determine guideline-based usage and prescriptions of OACs .The 
HAS-BLED (i.e., Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or 
predisposition, Liable INR, Elderly, Drugs/alcohol) is another score that is recommended by the 
European and Canadian AF guidelines to estimate the risk for bleeding in anticoagulated and 
standard patients over the next year (Roldán et al. 2013).  If the risk score utilizing the 
CHA2DS2-VASc is greater than 2 or the HAS-BLED score is less than 3, the patient is deemed 
appropriate for a prescribed OAC after risk and benefits have been discussed with the patient.  
Over estimation of bleeding risk is a significant barrier in prescribing OAC, especially among 
elderly patients (Lane & Lip 2013).  Elderly patients are often thought to be at a higher risk of 
bleeding as well as a fall risk.  To the contrary, these patients tend to be undertreated and are 
often times at a higher embolic risk due to increased age.  These risk management scores enabled 
the clinician to assess the most appropriate antithrombotic therapy for stroke prophylaxis in non-
valvular AF.   
Sampling Procedures/Setting 
The study population included all patients in one southern California, outpatient 
cardiology clinic who had been implanted with the Medtronic LINQ.  Patients without a history 
of AF but experiencing symptoms of palpitations, syncope, cryptogenic stroke, or suspected AF 
were enrolled.  
Measures 
Data were collected on patients with CHA2DS2-VASc scores of ranging from 0 to 10 
with two risk factors (e.g., CAD, renal impairment, sleep apnea).  Data were accessed and 
  
obtained from the patient’s electronic medical records and the Medtronic LINQ Carelink 
database utilizing a standardized data collection form.  This data form was then transferred into a 
password-protected Excel file for validation, auditing, and summarization.  The assessment tools, 
CHA2DS2-VASc and HAS-BLED, have been statistically validated in research studies.  
CHA2DS2VASc has a pooled C statistic of 0.667 (95% CI [0.651, 0.683]) for patients taking 
anticoagulation therapy and 0.675 (95% CI [0.656, 0.694]) for non-anticoagulation patients 
(Chen et al. 2013).  HAS-BLED demonstrated accuracy at predicting the risk of major bleeding 
(C statistic, 0.69, 95% CI [0.67, 0.72; Roldán et al., 2013).  Categorical variables such as the 
presence of hypertension, diabetes, congestive heart failure, and vascular disease were compared 
using chi-square.  Continuous or interval variables (e.g., age) were compared and correlated.   
Specific Aims 
This study examined the following study aims: 
AIM 1:  Describe the patient demographics (e.g., age, gender, ethnicity, AF) of patients receiving 
care in an outpatient cardiology clinic.   
AIM 2:  Describe the relationship between the dependent variable (AF) and independent 
variables (e.g., BMI) in patients receiving care in an outpatient cardiology clinic.   
AIM 3: Examine the frequency of AF diagnosis and the length of time to diagnosis in patients 
implanted with an ICM receiving care in an outpatient cardiology clinic.   
AIM 4:  Examine provider patterns of treatment with OACs. 
AIM 5:  Investigate documented considerations to diagnose or rule out OSA in a group of 
outpatient AF patients in a cardiology clinic. 
Data collection plan.  Once IRB approval was achieved, the data were de-identified to 
be compliant with Health Insurance Portability and Accountability Act (HIPPA) regulations.  
  
The database was password protected and documentation, including the codebook, was locked in 
a drawer in the researcher’s office.  All data will be destroyed 10 years after data collection.  
Patients with suspected AF with ICM between June 2014 and December 2018 were included in 
this convivence sample.  At the time of this study, AF lasting 5 minutes or longer was associated 
with a significantly-increased risk for stroke or systemic embolism in patients with a pacemaker 
(Healey, Connolly, Gold et al. 2012); therefore, AF episodes longer than 6 minutes was used to 
determine an episode.  After the patient was diagnosed with AF, the cardiologist or cardiology 
NP used the instruments to stratify the risk for stroke and bleeding.  If the CHA2DS2-VASc score 
was greater than or equal to 2 and the HAS-BLED score was less than 3, the patient was 
educated on embolic and bleeding risk and joint decision was made to start an OAC or continue 
current treatment.  Routine education was given to the patient at that time discussing the risks for 
stroke and bleeding as a standard procedure.   
Data Analysis 
Statistical analysis was conducted using Microsoft Excel© and SPSS (Version 24).  A 
power analysis using G*Power (Faul, 2014) suggested that the minimum number of patients 
needed for the study was 200 with a moderate effect size .20 and an alpha of .05 for a two-tailed 
test.  Descriptive statistics were used for demographics information with means, standard 
deviations, medians, skewness, and kurtosis, where appropriate.  Pearson r and Spearman rho 
correlations were used to examine the relationships between ordinal and interval data.  Chi 
square was used to test the frequencies between categorical variables.  Study outcomes were 
compared with the incidence of AF in patients and previous symptoms, such as palpitations, 
syncope, and cryptogenic stroke.  Secondary outcomes included the provider’s response to AF 
and in combination with the CHA2DS2-VASc and HAS-BLED scores.   
  
Study Timeline 
Three months were required for IRB approval.  Subsequently, the collection of data was 
done over 6 months. 
Theoretical Model 
The Quality Health Outcomes Model is the conceptual framework guiding this study 
(Figure 1).  This model helps evaluate and compare the quality that a system places on their 
subjects (Mitchell, Ferketich, & Jennings, 1998).  The model evaluates quality improvement and 
outcomes management through interventions within the system and the client (Mitchell et al).  
Through the Quality Health Outcomes Model, the study’s conceptual framework works with the 
independent variables of patient demographics and the ICM.  The dependent variables are the 
prescription of Nursing Implications 
 
Figure 1. Quality health outcomes model. Adapted from “Quality health outcomes model. 
American Academy of Nursing Expert Panel on Quality Health Care,” by P. H. Mitchell, S. 





The purpose of the study was to (a) describe patient demographics, (b) identify the 
percentage of patients identified with a diagnosis of AF, and (c) identify the length of time in 
days to diagnosis once an ICM was implanted into a cardiac patient.  Additionally, this study 
examined (d) whether there is an increase in frequency in OACs prescriptions with detection of 
AF, and (e) whether there was an increase in frequency for OSA in patients with AF.  
Inclusion criteria required that patients be adults aged 18 years or older, implanted with 
an ICM, and a primary diagnosis among the following: AF management, cryptogenic stroke, 
palpitations, suspected AF, syncope, or unknown reasons.  Exclusion criteria eliminated those 
patients who were already on anticoagulation for therapy for an indication other than AF and 
those who were hemodynamically unstable.  Patients diagnosed with valvular AF and patients 
already enrolled in a clinical trial were also excluded.  Furthermore, patients whose primary 
language at home was other than English or Spanish were also excluded.   
A portrayal of the sample population will be provided (Aim 1) along with descriptive 
statistics for the dependent and independent variables.  Findings for Aim 2-to-Aim 6 will follow. 
Incidental findings will also be presented as possible future research.   
Characteristics of the Sample  
Aim 1.  Describe the demographic information (e.g., age, gender, ethnicity, AF) for 
patients receiving care in an outpatient cardiology clinic. 
A total of 269 patients implanted with an ICM comprised the subjects of this research 
study.  A description of patients by gender and ethnicity are included in Table 1. Data about race 
was not incorporated into the patient charts and, therefore, could not be extracted. 
  
Table 1 
Patient Information by Gender and Ethnicity 























Participants in the study ranged from age 19-years to 93-years.  The average age was 
normally distributed (Skewness = -0.630; Kurtosis = 0.349).  Height (Skewness = -0.721; 
Kurtosis = 0.361) was also normally distributed but weight (Skewness = 0.966; Kurtosis = 1.108) 
was slightly leptokurtic and BMI was both positively skewed and leptokurtic (Skewness = 1.018; 






Patient Characteristics (with Normal Distribution) 
 N M SD 
Height (inches) 212 64.90 4.092 
Weight (lbs) 210 176.93 47.718 
BMI 207 29.17 6.143 
Age (years) 255 65.24 15.056 
 
After demographic information was extracted, patient records were examined to reveal 
the documented justification for patients receiving an ICM.  Table 3 categorizes these underlying 
conditions.  
Table 3 
Justification for Implant (N = 269) 
 N % 
AF Management 16 5.9% 
Cryptogenic Stroke 53 19.7% 
Palpitations 44 16.4% 
Suspected AF 38 14.1% 
Syncope 89 33.1% 
Unknown 29 10.7 
 
 The number of days from implant-to-AF detection (Skewness = 1.018; Kurtosis = 1.308) 
was not normally distributed (i.e., slight, positive skew; leptokurtic).  While the LINQ battery-
life was limited to 3 years (1,096 days), one subject was an outlier and AF was detected over 3 ½ 
  
years after implant (1,289 days). Descriptive information about CHA2DS2-VASc and HAS-
BLED scores, both ordinal scales, is also included on Table 4. 
Table 4 
Non-parametric Patient Measures 
 N Range Median Mode 
Days to detection 63 2, 1289 154 10, 14 
CHA2DS2-VASc 218 0, 8 4 4 
HAS-BLED 218 0, 5 3 3 
 
Comparisons of Independent Variables to AF 
Aim 2. Describe the relationship between the dependent variable (AF) and independent 
variables (e.g., BMI) in patients receiving care in an outpatient cardiology clinic.   
The second aim was to distinguish any differences in demographic information or 
diagnostic testing for those subjects whose ICM detected AF.  Significant differences were found 
in age (MNo = 63.18, MYes = 71.76), CHA2DS2-VASc scores (MNo = 3.73, MYes = 4.33), and HAS-
BLED scores (MNo = 2.56, MYes = 3.04). Height, weight, BMI, and Sleep Apnea Risk values were 




Significant Differences between Demographic/Diagnostic Information and AF Detection 






















Note. * p < .05; ** p < .01; *** p < .001. 
Next, for subjects whose ICM identified AF, an ANOVA was performed to see if the 
reason for implant differed among the continuous demographic and diagnostic variables.  For age 
and reason for ICM, patients with palpitations (M = 56.9 years) were significantly younger than 
patients with suspected AF (M = 69.33 years).   
The number of days reported to detect AF was significant by reason for the implant in the 
overall model; however, a Scheffé post-hoc test failed to identify any specific variable difference 
(range from 57.75 days for AF management to 387.53 days for syncope).  Table 6 summarizes 
these results. 
Table 6 
Differences in Demographics by Reason for Implant 
 df F p 
BMI 4, 184 1.123 .347 
Age 4, 226 3.929** .004 
Detect Days 4, 58 3.287* .017 
Note. * p < .05; ** p < .01; *** p < .001. 
For other demographic variables, there was no difference in detection days between 
genders (males 25/116, females 38/153).  While there were no differences between ethnicities or 
  
BMI and detection days, patients with suspected AF had a significantly higher frequency of AF 
detected by the ICM (χ2 = 25.920, p < .001).   
Assessing Time Needed to Diagnose AF 
Aim 3. Examine the frequency of AF diagnosis and the length of time to diagnosis in 
patients implanted with an ICM receiving care in an outpatient cardiology clinic.   
The third aim examined the length of time (days) to diagnosis.  Detection of AF occurred 
in 63 of the 269 subjects (23.4%) in this study.  The days needed to detect were then compared to 
standard methods of monitoring patients to see the capture rate of AF detection. The median 
detection days was 154.  Detection days ranged from 2 days to 1,289 days. Figure 2 displays 
these results.  
 
 
Figure 2. Number of days to detect AF with ICM compared with traditional monitors. 
Other type of arrythmias were also captured by the LINQ device. These rhythms are 
included in Table 7. 
Table 7 
  
Arrythmia Symptoms (N = 210) 
 N % 
Atrial Tachycardia (A Tach) 17 28.8 
Ventricular Tachycardia (V Tach) 4 6.8 
Supraventricular Tachycardia (SVT) 21 35.6 
Premature Ventricular Contractions (PVC) 9 15.3 
Bradycardia 8 13.6 
 
Treatment with Oral Anti-Coagulants (OACs) 
Aim 4.  Examine provider patterns of treatment with OACs.  
The fourth aim examined whether an increase in frequency occurred in patients 
prescribed OACs and detection of AF.  Out of the 63 patients (23.4%) where AF was detected, 
52.4% of those detected were on OACs (i.e., Eliquis, Xarelto).  There was a significantly higher 
frequency of patients with detected AF on Eliquis and Xarelto (χ2 = 58.462, p < .001).  The 
average age of patients on Eliquis was 77-years and on Xarelto was 68 years.  Descriptive 













Antiplatelet 34 12.6 4 6.3 
Eliquis 20 7.4 15 23.8 
Xarelto 33 12.3 18 28.6 
None 128 47.6 15 23.8 
Missing 54 20.1 9 14.3 
 
When patients were risk-stratified, two scoring tools are used to determine embolic 
(stroke) risk. For the instrument, CHA2DS2-VASc scores range from 0 to 8.  The median 
CHA2DS2-VASc score of the sample was 4.  Likewise, the HAS-BLED scores range from 0 to 8 
and this sample of patients had a median score of 3.   
Obstructive Sleep Apnea (OSA) and AF 
Aim 5.  Investigate documented considerations to diagnose or rule out OSA in a group of 
outpatient AF patients in a cardiology clinic. 
The fifth aim was to determine whether there was an increased frequency of OSA for 
patients with AF.  For this assessment of OSA risk, the STOP-BANG tool was used. Detailed 




Questionnaire Responses for STOP-BANG 
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Neck > 17” (Male) 

















The total score of the STOP-BANG assessment is used to assess the risk categories of 
OSA.  This instrument was administered through multiple attempts at telephone contact.  A total 
of 99 patients could be reached to complete this 8-question survey. Simple scoring can establish 
Low and Intermediate risks but High risk identification follows an algorithm outlined on p. 11.  




Assignment of Risk Score (N = 99) 
Risk Category (Score) N % 
Low (0-2) 19 7.1% 
Intermediate (3-4) 18 6.7% 
High (see algorithm) 62 23.0% 
Total 99 36.8% 
Missing data 170 63.2% 
 
To assess whether correlations existed between the STOP-BANG other data gathered in 
this study, Pearson r and Spearman rho calculations were performed based on the characteristics 
of each variable.  There was a positive correlation between STOP-BANG sleep apnea scores and 
BMI (ρ = .425, p < .001).  This could suggest that the higher one’s weight, the more likely that 
patient was at risk for OSA. 
In addition, there was an inverse correlation between STOP-BANG sleep apnea scores 
and AF detect days (ρ = -.504, p > .01).  This suggests that, the higher the STOP-BANG score, 
the fewer days pass before AF detection with the ICM.   
Incidental Findings 
A positive correlation was identified between the CHA2DS2-VASc scores and HAS-
BLED scores (r = .701, p < .001).  Specifically, as CHA2DS2-VASc scores increased, so did the 
HAS-BLED scores.   
Several significant correlations were seen between age and other variables collected in 
this study.  Age had a significant, moderate, positive correlation with the CHA2DS2-VASc scores 
(r = .523, p < .001).  Age was also moderately and positively correlated to the days needed to 
  
detect AF (ρ = .449, p < .001). Other significant and non-significant correlations are presented in 
Table 11 
Table 11 
Pearson r and Spearman rho (†) Correlations  
 CHA2DS2-VASc HAS-BLED Age BMI† Detect Days† 
CHA2DS2-VASc 1     
HAS-BLED .723*** 1    
Age .558*** .567*** 1   
BMI† -.255*** -.189** -.405*** 1  
Detect Days† .255 .063 .449*** -.240 1 
STOP-BANG .071 .241* -.029 .425*** -.504** 
Note. † Spearman rho. * p < .05; ** p < .01; *** p < .001. 
 Another incidental finding was uncovered among the limited number of OSA 
assessments. With documented OSA risk, information was extracted from the patient’s chart 
about their OSA diagnosis, referral, and follow-up (Table 12). 
Table 12 
Patients At-Risk for Sleep Apnea 
 N % 
Diagnosed with sleep disorder 16 5.9 
Sleep study ordered 2 0.7 
Negative per sleep study 3 1.1 




Data were collected between the hours of 8:00 a.m. and 5:00 p.m., Monday thru Friday.  
Another limitation was that the data were collected in a single office; therefore, this study 
population might not be generalizable to other settings.  Potential errors with medical records 
and data entry could have occurred with data input.  Potential confounders were rapid cardiac 
rhythms that could have been misdiagnosed and medical conditions that might have developed 
prior to implant.  Some patients failed with follow up by not connecting their monitors to the 
wall-unit transmitter or by not reconnecting or reprogramming the monitor when an error 
occurred.  Other patients may have decided to or needed a change of cardiologists due to 
insurance or preference.  Future studies should be designed to capture these potentially 
significant confounders. 
Summary 
This chapter presented the results of the data analysis for this study.  Each of the five 
research aims were outlined and interpreted.  Incidental findings were also presented to possibly 





Discussion of Findings 
This research addressed five areas of inquiry examining the available data on 269 patients 
who received an ICM and the potential assessment of AF.  The first aim of this retrospective 
study described the patient demographics.  The second aim stratified groups (e.g., reason for 
implant) and compared them with the length of time needed to identify AF.  The third aim 
analyzed the length of time in days to diagnosis.  Aim 4 examined the frequency of OAC 
prescriptions with the detection of AF.  The fifth aim scrutinized AF detection in patients who 
were also at risk or had been identified as having OSA. Finally, significant observations not 
incorporated into the five research aims were presented as evidence of the need for future 
research. 
This chapter will discuss and summarize the research design, method, data analysis, and 
overall results.  Nursing implications will also be addressed.   
This study provided profuse amounts of scientific knowledge regarding patients who 
received an ICM in a southern California cardiology outpatient clinic comparing and contrasting 
those treated for AF and those not yet diagnosed.  This retrospective database study design was 
performed in a setting that routinely-collected data on patients with ICMs implanted from June 1, 
2014 through December 31, 2018.  The sample had a similar distribution of age groups for males 
and females, but this population contained 37 more female patients.  Information about race and 
ethnicity was not routinely captured in the existing database.  A description of the 
average/median patient would be female, 5’5” in height, and 180 pounds in weight.  
  
The incidence of AF using an ICM (i.e., Medtronic LINQ) device in an outpatient clinic 
was 23.4%, similar to national studies stating that longer monitoring of cardiac rhythms 
increased the diagnosis of arrythmias.  Only 12.7% of detected AF occurred before 14 days, the 
maximum amount of time available through the use of other, traditional monitors in standard 
use; therefore, a surprising 87.3% of detected arrythmias found with the ICM could have 
remained unidentified.  To recap, shorter monitoring devices have arrythmia-detection 
capabilities up to 2 days (Holter monitor) or 7-14 days (Telemetry, Zio Patch), a disappointing 
statistic considering that the median number of days needed to detect AF in this study was 154 
days (M = 270 days).  For monitors that had been implanted within the last 18 months, 30.17% 
detected AF. This equals the CRYSTAL AF study (Sanna et al., 2014); however, the CRYSTAL 
AF study only examined patients with cryptogenic stroke and suspected AF and the present study 
included multiple symptomology, including palpitations and syncope.   
The ICM monitors are a useful way to identify arrythmias without the patient being 
responsible for the maintenance and control the device.  The automatic download by wireless 
function decreases data entry error.   
Intracardiac monitors are also useful in assisting with stroke-risk stratification and 
bleeding risks among patients diagnosed with AF.  Previously, AF patients at risk for stroke were 
prescribed warfarin; however, the potential benefit of OACs was found to significantly improve 
the composite of stroke or systemic embolic events by 19% when compared with warfarin (Hart, 
Pearce, & Aguilar, 2007).  Presently, OACs are used more frequently, particularly after the 
PINNACLE trial (Hsu et al., 2016).  In the PINNACLE Trial, less than 55% of patients who 
were considered at moderate-to-high risk for stroke received OACs; this study found that 63.5% 
of those patients were treated with OACs.  This increase in treatment for this study may be due 
  
in part to the new OACs. The number of patients who are not on OACs could be explained by 
the WATCHMAN procedure or fall risk, both contraindications for OAC use.  These factors 
were not taken into account for not prescribing OACS in this patient population.  During the 
PINNACLE trial, warfarin was the only option for anticoagulation.  Newer anticoagulants have 
lower bleeding risk profiles; are easier to prescribe; simpler to manage, with no weekly blood 
draws; and do not interfere with foods or most other medications.  This may provide some 
security in prescribing habits by clinicians.  These factors were not taken into account for not 
prescribing OACS in this patient population.   
Future Studies 
Future studies should examine links between OSA and the detection of AF.  With an 
inadequate number of responders to the STOP-BANG instrument (n no = 74, n yes = 25), 
statistical significance could not be achieved in this study but the data were trending toward a 
higher score on the STOP-BANG score in those patients diagnosed with AF.  As the STOP-
BANG scores were normally distributed (M = 3.93, Median = 4, Mode = 4, SD = 1.599, 
Skewness = -.188, Kurtosis = -.214), a comparison was made between patients diagnosed with 
AF and those who did not have documented AF. The comparison between these groups was not 




Figure 3. Comparison of STOP-BANG scores between AF and non-AF patients. 
Future studies should examine OSA and AF detection in larger sample size and multiple 
locations.  In this study, responses were captured by phoning each patient 1-to-3 times to answer 
a subjective questionnaire, STOP-BANG.  As STOP-BANG scores increased, the number of 
days needed to detect AF was lower.  Most patients in this research study were at moderately 
high risk for OSA (Median = 4).  BMI was not significant in relation to AF, but presents another 
factor worthy of further examination. 
Implications for Nursing 
This study reveals pivotal points for focused research with AF.  With new, longer 
monitoring capabilities, the identification of disease and decrease in morbidity for AF patients is 
more promising.  This research study aligns with larger studies performed (Hsu et al, 2016).  
Continued research with AF should be conducted to provide adequate information for the 
implementation of tailored intervention programs that encourage extended monitoring devices, 
encourage standardized protocols and guidelines for arrythmias management, foster and educate 
policymakers, and address insurance loopholes that require shorter monitor devices.  Prevention 
  
of major comorbidities (e.g., thromboembolic events) are also important and possible with an 
increase in identifying AF.  With an increase in the cost of rehabilitation and level of care needed 
for patients after these events, the benefit from identifying this cardia arrythmia sooner will save 
health care costs and improve quality of life.  The adoption and utilization of health information 
technology is still relatively low among patients with chronic disease. 
Conclusion 
As evidenced by this study, most patients would not have been identified with AF 
utilizing the shorter-duration monitoring devices typically used as the first line of treatment.  
Longer monitoring capabilities promise early identification of disease and reduction in morbidity 
for AF patients and will also increase awareness and aid in decision-making when seeing patients 
in the outpatient setting.  The prevention of major comorbidities such as thromboembolic events 
are also possible with an increase in identifying AF.  The cost-avoidance of rehabilitative care 
for AF sequela may be realized by identifying this cardia arrythmia sooner.  
  
References 
Aguilar, M. & Hart, R. (2005). Oral anticoagulants for preventing stroke in patients with non-
valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. 
Cochrane Database of Systematic Reviews, 3, CD001927. 
doi:10.1002/14651858.CD001927.pub2 
American Heart Association. (n.d.). What is atrial fibrillation (AFib or AF). Retrieved March 29, 
2019 from https://www.heart.org/en/health-topics/atrial-fibrillation/what-is-atrial-
fibrillation-afib-or-af 
Anter, E., Di Biase, L., Contreras-Valdes, F. M., Gianni, C., Mohanty, S., Tschabrunn, C. M., . . . 
Josephson, M. E. (2017) Atrial substrate and triggers of paroxysmal atrial fibrillation in 
patients with obstructive sleep apnea. Circulation: Arrhythmia and Electrophysiology, 
10. doi:10.1161/CIREP.117.005407 
Atrial Fibrillation Investigators. (1994). Risk factors for stroke and efficacy of antithrombotic 
therapy in atrial fibrillation. Analysis of pooled data from five randomized control trials. 
Archives of Internal Medicine, 154, 1449-1457. 
Barbarossa A., Guerra F., & Capucci A. (2014). Silent atrial fibrillation: A critical review. 
Journal of Atrial Fibrillation, 7, 1138. doi:10.4022/jafib.1138 
Benjamin, E. J., Wolfe, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. 
(1998). Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. 
Circulation, 98, 946-952.  
Blackshear, J. L., & Odell, J. A. (1996). Appendage obliteration to reduce stroke in cardiac 
surgical patients with atrial fibrillation. Annuals of Thoracic Surgery, 61, 755-759. 
doi:10.1016/0003-4975(95)00887-X 
  
Brignole, M., Alboni, P., Benditt, D. G., Bergfeldt, L., Blanc, J. J., Bloch Thomsen, P. E., . . . 
Wieling W. (2004) Guidelines on management (diagnosis and treatment) of syncope - 
Update 2004: The Task Force on Syncope, European Society of Cardiology. European 
Heart Journal, 25, 467-537. doi:10.1016/j.ehj.2004.09.004 
Butt, M., Dwivedi, G., Khair, O., & Lip, G.Y. (2010). Obstructive sleep apnea and 
cardiovascular disease. International Journal of Cardiology, 139, 7-16. 
doi:10.1016/j.ijcard.2009.05.021 
Capucci, A., Santini, M., Padeletti, L., Gulizia, M., Botto, G. L., Boriani, G., . . .Italian AT500 
Registry Investigators. (2005). Monitored atrial fibrillation duration predicts arterial 
embolic events in patients suffering from bradycardia and atrial fibrillation implanted 
with antitachycardia pacemakers. Journal of the American College of Cardiology, 46, 
2054-2072. doi:10.1016/j.jacc.2005.07.044 
Chen, J.-Y., Zhang, A.-D., Lu, H.-Y., Guo, J., Wang, F.-F., & Li, Z.-C. (2013). CHADS2 versus 
CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in 
patients with atrial fibrillation: A systematic review and meta-analysis. Journal of 
Geriatric Cardiology, 10, 258-266. doi:10.3969/j.issn.1671-5411.2013.03.004 
Cleveland Clinic. (n.d.). Atrial fibrillation (Afib). Retrieved October 1, 2018 from 
http://my.clevelandclinic.org/services/heart/disorders/arrhythmia/atrial-fibrillation-afib.  
Colilla, S., Crow, A., Petkum, W., Singer, D., Simon, T., & Liu X. (2013).  Estimates of current 
and future incidence and prevalence of atrial fibrillation in the U.S. adult population.  Am 
J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. 
Coll-Vinent, B., Martin, A., Malagon, F., Suero, C., Varona M., Cancio, M., . . . HERMES-AF 
Investigators. (2015). Stroke prophylaxis in atrial fibrillation: Searching for management 
  
improvement opportunities in the emergency department: The HERMES-AF study. 
Annals of Emergency Medicine, 65, 1-12. doi:10.1016/j.annemergmed.2014.07.016 
Coll-Vinent, B., Pacheco, G., Junyent, M., Benito, L., Hoyo, J., Garcia, A., . . . Mont, L. (2007). 
Impact of implementing common guidelines at different care levels in a healthcare area 
on the improvement of atrial fibrillation treatment. Revista Española de Cardiología, 60, 
392-403. doi:10.1016/S1885-5857(07)60172-8 
Faul, F. (2014). G*Power (Version 3.1.9.2) [Software]. Düsseldorf, FRG: Universität Kiel. 
Freeman, J. V., Simon, D-J. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., . . . Piccini, 
J. P. (2015). Association between atrial fibrillation symptoms, quality of life, and patient 
outcomes. Circulation, 8, 393-402. doi:10.1161/CIRCOUTCOMES.114.001303 
Ganesan, A. N., Chew, D. P., Hartshorne, T., Selvanayagam, J. G., Aylward, P. E., Sanders, P., 
& McGavigan, A. D. (2016). The impact of atrial fibrillation type on the risk of 
thromboembolism, mortality, and bleeding: A systematic review and meta-analysis. 
European Heart Journal, 37, 1591-1602. doi:10.1093/euroheartj/ehw007 
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. 
(2001). Prevalence of diagnosed atrial fibrillation in adults: National implications for 
rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in 
Atrial Fibrillation (ATRIA) Study. JAMA, 285, 2370-2375. 
doi:10.1001/jama.285.18.2370 
Goldstein, L. B., Bushnell, C. D., Adams, R. J., Appel, L. J., Braun, L. T., Chaturvedi, S., . . . 
Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care 
and Outcomes Research. (2011). Guidelines for the primary prevention of stroke: A 
  
guideline for healthcare professionals from the American Heart Association/American 
Stroke Association. Stroke, 42, 517-584. doi:10.1161/STR.0b013e3181fcb238 
Gonzaga J. M., & Weber R. J. (2008). Advanced practice programs in hospital pharmacy: 
Anticoagulation management. Hospital Pharmacy, 43, 60-65. doi:10.1310/hpj4301-60 
Hart, R. G, Pearce, L. A, & Aguilar, M. I. (2007). Meta-analysis: Antithrombotic therapy to 
prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal 
Medicine, 146, 857-867. doi:10.7326/0003-4819-146-12-200706190-00007 
Harvard Medical Publishing. (2018). Atrial fibrillation: Common, serious, treatable. Retrieved 
October 1, 2018 from https://www.health.harvard.edu/heart-health/atrial-fibrillation-
common-serious-treatable 
Healey, J. S., Alings, M., Ha, A., Leong-Sit, P., Birnie, D. H., de Graaf, J. J., . . . ASSERT-II 
Investigators. (2017). Subclinical atrial fibrillation in older patients. Circulation, 136, 
1276-1283. doi.org/10.1161/CIRCULATIONAHA.117.028845 
Healey, J. S, Connolly, S. J, Gold, M. R, Isreal, C. W., Van Gelder, I. C., Capucci, A., . . . 
ASSERT Investigators. (2012). Subclinical atrial fibrillation and the risk of stroke. New 
England Journal of Medicine, 366, 120-129. doi:10.1056/NEJMoa1105575 
Healey, J. S., Oldgren, J., Ezekowitz, M., Zhu, J., Pais, P., Wang, J. . . Connolly, S. J. (2016). 
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with 
atrial fibrillation: A cohort study. Lancet, 388, 1161-1169. doi:10.1016/S0140-
6736(16)30968-0 
Hsu, J. C., Maddox, T. M., Kennedy, K. F., Katz, D. F., Marzec, L. N., Lubitz, S. A., . . . 
Marcus, G. M. (2016). Oral anticoagulant therapy prescription in patients with atrial 
  
fibrillation across the spectrum of stroke risk: Insights from the NCDR PINNACLE 
Registry. JAMA Cardiology, 1, 55-62. doi:10.1001/jamacardio.2015.0374 
January, C. T., Wann, L. S., Alpert J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., . . . Yancy, 
C. W. (2014). 2014 AHA/ACC/HRS guidelines for the management of patients with 
atrial fibrillation: Executive summary. Journal of American College of Cardiology, 64. 
2014. doi:10.1016/j.jacc.2014.03.021 
Key, J. P. (1997). Research design in occupational education: Module R12: Descriptive research. 
Retrieved from 
https://www.okstate.edu/ag/agedcm4h/academic/aged5980a/5980/newpage110.htm 
Kirchhof, P., Benussi S., Kotecha D. Ahlsson, A., Atar, D., Casadei, B, . . . ESC Scientific 
Document Group. (2016). 2016 ESC guidelines for the management of atrial fibrillation 
developed in collaboration with EACTS. European Heart Journal, 27, 2893-2962. 
doi:10.1093/eurheartj/ehw210  
Kirchhof, P., Breithardt, G., Aliot E., Al Khatib, S., Apostolakis, S., Auricchio, A., . . . Camm, 
A. J. (2013). Personalized management of atrial fibrillation: Proceedings from the fourth 
Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus 
conference. EPEuropace, 15, 1540-1556. doi:10.1093/europace/eut232 
Lane, D. A., & Lip, G. Y. H.  (2012). Use of the CHA2DS2-VASc and HAS-BLED scores to aid 
decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation, 
126, 860-865. doi:10.1161/CIRCULATIONAHA.111.060061  
Lang, E. S. C., Clement, C. M., Brison, R. J., Rowe, B. H., Borgundvaag, B., & Langhan, T. 
(2010). Are emergency physicians initiating anticoagulation in discharged patients with 
  
atrial fibrillation and high CHADS scores? Canadian Journal of Emergency Medicine, 
12, 250.  
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010). Refining 
clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation 
using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. 
Chest, 137, 263-272. doi:10.1378/chest.09-1584 
Lim, H. S., & Lip, G.Y H. (2008). Asymptomatic atrial fibrillation on device interrogation. 
Journal of Cardiovascular Electrophysiology, 19, 891-893. doi:10.1111/j.1540-
8167.2008.01194.x 
Lin, H. J., Wolf, P. A., Benjamin, E. J., Belanger, A. J., & D’Agostino, R. B. (1995). Newly 
diagnosed atrial fibrillation and acute stroke: The Framingham Study. Stroke, 26, 1527-
1530. doi:10.1161/01.STR.26.9.1527 
Mannarino, M. R., Di Filippo, F., & Pirro, M. (2012). Obstructive sleep apnea syndrome. 
European Journal of Internal Medicine, 23, 586-593. doi:10.1016/j.ejim.2012.05.013 
Mitchell, P. H., Ferketich, S., Jennings, B. M., & American Academy of Nursing Expert Panel 
on Quality Health Care. (1998). Quality Health Outcomes Model. Journal of Nursing 
Scholarship, 30, 43-46. doi:10.1111/j.1547-5069.1998.tb01234.x 
Miyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaraatna, W. P., . . . 
Tsang, T. S. M. (2006). Secular trends in incidence of atrial fibrillation in Olmsted 
County, Minnesota, 1980 to 2000, and implications on the projections for future 
prevalence. Circulation, 114, 119-25. doi:10.1161/CIRCULATIONAHA.105.595140 
Mozaffarian, D, Benjamin, E. J., Go, A.S, Arnett, D. K., Blaha, M. J., Cushman, M., . . . 
American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 
  
(2015). Heart disease and stroke statistics – 2015 update: A report from the American 
Heart Association. Circulation, 131, 434-441. doi:10.1161/CIR.0000000000000157 
Nasir, J. M., Pomeroy W, Marler A, Hann, M., Baykaner, T., Jones, R., . . . Kindsvater, S. 
(2017). Predicting determinants of atrial fibrillation or flutter for therapy elucidation in 
patients at risk for thromboembolic events (PREDATE AF) study. Heart Rhythm, 14, 
955-961. doi:10.1016/j.hrthm.2017.04.026 
National Stroke Association. (n.d.) Making the afib-stroke connection. Retrieved October 1, 
2018 from https://www.stroke.org/understand-stroke/preventing-a-stroke/afib-stroke-
connection/ 
Polit, D. F., & Beck, C. T. (2012). Nursing research: Generating and assessing evidence for 
nursing practice (9th ed.) Philadelphia, PA: Wolters Kluwer Health. 
Quirino, G., Giammaria, M., Corbucci, G., Pistelli, P., Turri, E., Mazza, A., . . . Barold, S. S. 
(2009). Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: 
Relationship to symptoms and other variables. Pacing and Clinical Electrophysiology, 32, 
91-98. doi:10.1111/j.1540-8159.2009.02181.x 
Reiffel, J. A., Verma, A., Kowey, P. R., Halperin, J. L., Gersh, B. J., Wachter, R., . . . REVEAL 
AF Investigators. (2017). Incidence of previously undiagnosed atrial fibrillation using 
insertable cardiac monitors in a high-risk population: The REVEAL AF Study. JAMA 
Cardiology, 2, 1120-1127. doi:10.1001/jamacardio.2017.3180 
Roldán V., Marin F., Manzano-Fernández S., Gallego P., Vilchez J. A., Valdes M., . . . Lip G. Y. 
H. (2013). The HAS-BLED score has better prediction accuracy for major bleeding than 
CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. 
  
Journal of the American College of Cardiology, 62, 2199-2204. 
doi:10.1016/j.jacc.2013.08.1623 
Sanna, T., Diener, H. C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., . . . 
CRYSTAL AF Investigators. (2014). Cryptogenic stroke and underlying atrial 
fibrillation. New England Journal of Medicine, 370, 2478-2486. 
doi:10.1056/NEJMoa1313600 
Schnabel, R. B., Rienstra, M., Sullivan, L. M., Sun, J. X., Moser, C. B., Levy, D., . . . Benjamin, 
E. J. (2013). Risk assessment for incident heart failure in individuals with atrial 
fibrillation. Eurpean Journal of Heart Failure, 15, 843-849. doi:10.1093/eurjhf/hft041 
Steinhubl, S. R. (2018). ACC 18, Abstract 402-419. In M. L. Zoler, Boost AF diagnosis: ECG 
patch found 9 times more than conventional means. Cardiology News, 16(5), 1, 11. 
Steinhubl, S. R., Waalen, J., Edwards, A. M., Ariniello, L. M., Mehta, R. R., Ebner, G. S., . . . 
Topol, E. J. (2018). Effect of a home-based wearable continuous ECG monitoring patch 
on detection of undiagnosed atrial fibrillation: The mSToPS randomized clinical trial. 
JAMA, 320, 146-155. doi:10.1001/jama.2018.8102 
Steinhubl, S. R., Waalen, J., Edwards, A. M., Mehta, R. R., Ariniello, L., Ebner, G., . . . Topol, 
E. (2017). Abstract 13757: A nationwide trial of screening for undiagnosed atrial 
fibrillation in an at-risk population using a self-applied ECG recording patch sensor: 
Results of the randomized component of the mHealth Screening to Prevent Strokes 
(mSToPS) trial. Circulation, 136(Suppl 1), A13757. 
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. (2002). A population-based study of the 
long-term risks associated with atrial fibrillation: 20-year follow-up of the 
Renfrew/Paisley study. American Journal of Medicine, 113, 359-364.  
  
Stiell, I. G., & Macle, L., & CCS Atrial Fibrillation Guidelines Committee. (2011). Canadian 
Cardiovascular Society atrial fibrillation guidelines 2010: Management of recent-onset 
atrial fibrillation and flutter in the emergency department. Canadian Journal of 
Cardiology, 27(2), 38-46. doi.org/10.1016/j.cjca.2010.11.014 
Van Gelder, I. C., Healey, J. S., Crijns, H. J. G. M., Wang, J., Hohnloser, S. H., Gold, M. R., . . . 
Connolly, S. J. (2017). Duration of device-detected subclinical atrial fibrillation and 
occurrence of stroke in ASSERT. European Heart Journal, 38, 1339-1344. 
doi.org/10.1093/eurheartj/ehx042 
Wang, T. J., Larson, M. G., Levy, D. Vasan, R. S., Leip, E. P., Wolf, P. A., . . . Benjamin, E. J. 
(2003). Temporal relations of atrial fibrillation and congestive heart failure and their joint 
influence on mortality: The Framingham Heart Study. Circulation, 107, 2920-2925. 
doi.org/10.1161/01.CIR.0000072767.89944.6E 
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991). Atrial fibrillation as an independent risk 
factor for stroke: The Framingham Study. Stroke, 22, 983-988. 
doi.org/10.1161/01.STR.22.8.983 
Ziegler, P. D., Koehler, J. L., & Mehra, R. (2006). Comparison of continuous verses intermittent 




USD Institutional Review Board Approvals 
 
  
   
  
 
  
  
 
  
 
  
 
